RAAS antagonist therapy for prevention of atrial fibrillation in hypertension / 中华全科医师杂志
Chinese Journal of General Practitioners
;
(6): 81-84, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-734849
ABSTRACT
Hypertension is the most common and controlable risk factor of atrial fibrillation (AF).Resin-angiotensin-aldosterone system (RAAS) antagonist therapy may reduce atrial remodeling and hold promise as “upstream” therapy for AF,especially for the patients with left ventricular hypertrophy and left ventricular dysfunction.The RAAS antagonist therapy for prevention of AF in hypertensive patients needs to be further explored in large scale randomized studies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Ensaio Clínico Controlado
/
Fatores de risco
Idioma:
Chinês
Revista:
Chinese Journal of General Practitioners
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS